% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ohnmacht:282511,
      author       = {A. J. Ohnmacht and A. Stahler and S. Stintzing$^*$ and D.
                      P. Modest and J. W. Holch$^*$ and C. B. Westphalen and L.
                      Hölzel and M. K. Schübel and A. Galhoz and A. Farnoud and
                      M. Ud-Dean and U. Vehling-Kaiser and T. Decker and M.
                      Moehler and M. Heinig and V. Heinemann and M. P. Menden},
      title        = {{T}he {O}ncology {B}iomarker {D}iscovery framework reveals
                      cetuximab and bevacizumab response patterns in metastatic
                      colorectal cancer.},
      journal      = {Nature Communications},
      volume       = {14},
      number       = {1},
      issn         = {2041-1723},
      address      = {[London]},
      publisher    = {Nature Publishing Group UK},
      reportid     = {DKFZ-2023-01800},
      pages        = {5391},
      year         = {2023},
      abstract     = {Precision medicine has revolutionised cancer treatments;
                      however, actionable biomarkers remain scarce. To address
                      this, we develop the Oncology Biomarker Discovery (OncoBird)
                      framework for analysing the molecular and biomarker
                      landscape of randomised controlled clinical trials. OncoBird
                      identifies biomarkers based on single genes or mutually
                      exclusive genetic alterations in isolation or in the context
                      of tumour subtypes, and finally, assesses predictive
                      components by their treatment interactions. Here, we utilise
                      the open-label, randomised phase III trial (FIRE-3, AIO
                      KRK-0306) in metastatic colorectal carcinoma patients, who
                      received either cetuximab or bevacizumab in combination with
                      5-fluorouracil, folinic acid and irinotecan (FOLFIRI). We
                      systematically identify five biomarkers with predictive
                      components, e.g., patients with tumours that carry chr20q
                      amplifications or lack mutually exclusive ERK signalling
                      mutations benefited from cetuximab compared to bevacizumab.
                      In summary, OncoBird characterises the molecular landscape
                      and outlines actionable biomarkers, which generalises to any
                      molecularly characterised randomised controlled trial.},
      cin          = {BE01 / MU01},
      ddc          = {500},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37666855},
      doi          = {10.1038/s41467-023-41011-4},
      url          = {https://inrepo02.dkfz.de/record/282511},
}